We prospectively assessed autologous stem cell transplantation for consolidation treatment in a trial of intensive chemotherapy in high risk myelodysplastic syndromes (MDS). In this trial, patients aged 55 years or less with no HLA-identical sibling and achieving CR were scheduled to receive unmanipulated autologous bone marrow transplantation (ABMT) preceded by a consolidation chemotherapy course. Forty-two of the 83 patients aged 55 years or less included in the trial (51%) achieved CR. Three were allografted in CR. Twenty-four of the remaining 39 patients who achieved CR (62%) received ABMT (16 patients) or autologous peripheral blood stem cell transplantation (APSCT) (eight patients). Indeed, as bone marrow harvest was often insufficient, APSCT was subsequently proposed after mobilization by consolidation chemotherapy followed by G-CSF. The conditioning regimen combined cyclophosphamide and busulfan. ABMT and APSCT were performed 1-7 months (median 3) after CR achievement. Hematological reconstitution occurred in all patients and tended to be faster after APSCT than ABMT although not significantly. Three patients died from the procedure, nine relapsed after 2-26 months and 12 (50%) were still in CR after 8-55 months. In autografted patients, median Kaplan-Meier disease-free survival and survival were 29 and 33 months from the autograft, respectively. Thus, ABMT or APSCT can be performed in almost two-thirds of MDS patients who achieve CR with intensive chemotherapy. PBSC collection may yield higher numbers of stem cells than marrow collection in some cases, and could improve the percentage of MDS patients autografted in CR. Longer follow-up is required to determine if autograft will prolong CR duration in at least some patients.
Introduction
Myelodysplastic syndromes (MDS) are bone marrow stem cells disorders characterized by ineffective hematopoiesis leading to blood cytopenias and by a high incidence of progression to acute myeloid leukemia (AML). [1] [2] [3] Treatment of MDS overall remains disappointing. Allogeneic bone marrow transplantation (BMT) can be curable in about 40% of cases, but it is restricted to the rare MDS patients aged less than 50-55 years with an HLA-matched donor. 4, 5 Low-dose chemotherapy with AraC or other drugs generally gives low response rates, whereas growth factors do not appear to have any effect on the disease course. 6, 7 Intensive anthracycline AraC chemotherapy, in MDS and AML following MDS, has given lower Correspondence: P Fenaux, Service des Maladies du Sang, CHU, 1 place de Verdun, 59037 Lille, France; Fax: 33 03 20 44 40 94 Received 13 July 1998; accepted 15 January 1999 complete remission (CR) rates than in de novo AML in most published experiences. [8] [9] [10] [11] [12] [13] [14] [15] Reasons for the poor response rates to chemotherapy in MDS could include in particular a higher incidence of expression of the multidrug resistance (mdr) gene in MDS than in de novo AML. 16 Recently, our two groups, the Groupe Ouest-Est d'étude des Leucémies aiguës myé-loïdes (Goelams group) and the Groupe Français des Myélo-dysplasies (French MDS group: GFM), found in a randomized study that modulation of mdr expression by quinine improved CR rates obtained with intensive chemotherapy in MDS patients expressing the mdr gene. 17 Intensive chemotherapy, in MDS and AML following MDS, also gives shorter CR duration than in de novo AML, and a very low proportion of long-term survivors (14% at 4 years in our experience) is observed. [1] [2] [3] 7, 8, [8] [9] [10] [11] [12] [13] [14] Therefore, in an attempt to improve long-term outcome, several groups have performed autologous stem cell transplantation, [18] [19] [20] [21] either bone marrow (ABMT) or peripheral stem cell transplantation (APSCT), as consolidation treatment in MDS patients who achieved CR after intensive chemotherapy. Only retrospective studies of ABMT or APSCT have been reported so far. In the largest reported study where 79 patients received ABMT, the treatment-related mortality was 9% and the 2 year disease-free survival (DFS) post ABMT was 34%. 21 In a study of intensive chemotherapy in MDS and AML post MDS, undertaken by the Goelams and GFM groups, 17 patients younger than 55 years who achieved CR and had no HLA-identical sibling were scheduled to receive autologous stem cell transplantation. We present here the results of this prospective study.
Patients and methods
Between March 1992 and May 1996, the GFM and the GOE-LAMS groups conducted a randomized trial of mitoxantroneAraC chemotherapy with or without quinine in MDS and AML post MDS. 17 This trial had been approved by the ethical committee of Dijon (France) according to French law. Inclusion criteria were: (1) MDS, according to FAB criteria; (2) age р65 years; (3) marrow blasts у5%, ie refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-T), chronic myelomonocytic leukemia (CMML, or MDS having progressed to AML (AML post MDS); (4) no previous chemotherapy; (5) absence of an HLA-identical sibling; (6) patient diagnosed in a center where PGP expression was assessable or adequate material was sent to a referral center; and (7) 3 , hemoglobin Ͼ10 g without transfusion requirement; (3) normalization of the karyotype if initially abnormal (at least 10 mitoses examined); (4) disappearance of major myelodysplastic features in the bone marrow (with the exception of mild dysplasia, as seen after chemotherapy). Partial remission (PR) criteria included: Ͻ5% marrow blasts and persistence of cytopenia(s) but with an increase in neutrophils by at least 1000/mm 3 , of platelets by at least 50 000/mm 3 , of hemoglobin by at least 2 g/dl, or disappearance of cytopenias but persistence of either major myelodysplastic features or cytogenetic abnormalities. Death in aplasia was defined by death during the period of aplasia following chemotherapy administration. Failure corresponded to all other situations. In case of failure and partial remission, treatment options were left open but administration of a salvage course identical to the induction course and identical to the consolidation course, respectively, was suggested.
Patients aged 55 years or less included in the trial who achieved CR were scheduled to receive ABMT preceded by a consolidation chemotherapy course consisting of mitoxantrone 12 mg/m 2 /day for 2 days and AraC 500 mg/m 2 /12 h for 4 days. After recovery from this course of consolidation therapy, persistence of CR was checked. Patients who remained in CR underwent, for ABMT, autologous marrow harvest under general anesthesia with the intention to harvest a minimum yield of 2 × 10 8 nucleated cells per kilogram of body weight. The bone marrow was cryopreserved in the presence of RPMI, 10% autologous serum and 10% DMSO following a step controlled freezing procedure and were stored at −196°C in liquid nitrogen. The number of CFU-GM was assayed prior to cryopreservation and immediately after thawing, before reinfusion. In more recently included patients, APSCT rather than ABMT was used. After checking persistence of CR, peripheral blood stem cell (PBSC) harvest was made after mobilization using the same mitoxantrone-AraC consolidation chemotherapy course followed by G-CSF, 10 g/kg/24 h, subcutaneously until PBSC harvest. PBSC collection was started at an absolute neutrophil count у0.5-1 × 10 9 /l following consolidation chemotherapy, and continued until at least 2 × 10 6 CD34 + cell/kg were obtained. Two to three aphereses were performed. Nine to 15 liters of blood were processed for each apheresis. G-CSF was continued until completion of the collections. The harvested cells were cryopreserved following similar procedures as described above for bone marrow cryopreservation.
The conditioning regimen for ABMT and APSCT consisted of cyclophosphamide 50 mg/kg/day for 4 days and busulfan 4 mg/kg/day for 4 days. No growth factor was used after bone marrow or PBSC reinfusion.
Prognostic factors were assessed using the appropriate regression models, either logistic regression or Cox model. These factors, derived from previous studies [22] [23] [24] were age, sex, FAB classification and cytogenetic abnormalities.
Results
From October 1992 to May 1996, 131 MDS patients were included in the randomized trial with quinine. 17 Fifty-seven patients (43.5%) achieved CR, including 47% of the patients who received quinine and 41% of the patients who did not receive quinine.
Eighty-three of the patients included in this trial were aged 55 or less and were thus potential candidates for autologous stem cell transplantation if they achieved CR. Their initial characteristics, including FAB classification, cytogenetic findings and classification according to the international prognostic scoring system (IPSS, Ref. 24) are shown in Table 1 . Ten of them (12%) had therapy-related MDS. Forty-two of the 83 patients (51%) achieved CR, 13 (16%) achieved PR, 15 (18%) had resistant disease and 13 (15%) died during aplasia. Three of the patients who achieved CR were allografted, two of them from an unrelated donor. The latter two patients died 3 and 18 months after transplantation from graft-versus-host disease. The third allografted patient was still alive in first CR, 2 years from transplantation.
Twenty-four of the remaining 39 patients who achieved CR (62%) received ABMT (16 patients) or APSCT (eight patients). Reasons for not performing ABMT or APSCT in the remaining 15 complete remitters included early relapse (five patients), poor clinical condition after CR achievement (four patients), poor stem cell harvest (four patients) and patient refusal (two patients). Early relapses occurred 1, 1, 1.5, 2 and 2 months respectively after CR achievement, including two cases where relapse was diagnosed just before bone marrow harvest. Three of the five patients with early relapse and successfully karyotyped at the time of treatment onset had an unfavorable karyotype: −7 in one case, and complex abnormalities in the two remaining patients. Poor clinical condition was caused by invasive aspergillosis in two cases, cardiac failure probably due to mitoxantrone in one patient and renal failure in the remaining case. Poor stem cell harvest corresponded to poor bone marrow harvest in two patients (no peripheral stem cell harvest was made in those two patients) and poor marrow plus poor peripheral stem cell harvest in the two remaining cases. Successful PSC harvest was obtained in two additional cases where bone marrow harvest was insufficient. APSCT rather than ABMT was proposed in all recently treated patients, after mobilization by consolidation chemotherapy followed by G-CSF. Except for the patient with cardiac failure who was consolidated by low-dose AraC, the remaining non-autografted patients received three to six consolidation courses of mitoxantrone 12 mg/m 2 day 1 and AraC 60 mg/m 2 /12 h days 1-5, with no treatment-related mortality.
Bone marrow and PSC harvest was performed 0.5-5 months (median 2.5 months) after CR achievement. ABMT and APSCT was performed 1-7 months (median 3 months) after CR achievement. After thawing, the median number of harvested CFU-GM was 13. leukopenia, neutropenia and thrombocytopenia was 16 (range 11-18), 20 (range 11-23) and 52 days (range 11-80), respectively (differences not significant).
Median survival of the 83 patients aged р55 years included in the trial was 14 months. Median survival of the 42 patients aged р55 and who achieved CR was 21 months. Median follow-up of the 24 autografted cases was 19 months from the autograft (21 months after ABMT and 17 months after APSCT). Three patients died from the procedure: two from sepsis and one from veno-occlusive disease 120, 30 and 30 days after ABMT, respectively. No toxic death was observed after APSCT. Nine patients relapsed after 2-26 months, including six of the 16 ABMT and three of the eight APSCT; 12 patients (50%), including seven ABMT and five APSCT, were still in CR after 8-55 months.
Six patients relapsed with the same FAB type as at the onset of chemotherapy, including three RAEB-T, two RAEB and one AML. Two patients with RAEB-T at the onset of chemotherapy relapsed with AML, and one case with AML at the onset of chemotherapy relapsed with RA. Treatment of relapse consisted of intensive chemotherapy in two AML cases, and supportive care in the remaining seven patients. Of the two relapsing patients who were retreated with intensive chemotherapy, one showed resistance and rapidly died and one achieved a second CR, but relapsed after 2 months. He was then allografted with an HLA-compatible unrelated donor and achieved a third CR. He remained in persistent CR, 2 years after the allograft. Of the seven relapsed patients who received supportive care, five died within 6 months of relapse and the remaining two patients, who relapsed with RAEB, died after 25 and 40 months, respectively.
In autografted patients, median Kaplan-Meier DFS and survival were 29 and 33 months from the autograft, respectively (Figures 1 and 2) . In Cox univariate analysis, gender was the only prognostic factor of the outcome of autograft: males had both shorter DFS (median not reached in females vs 14 months in males, P = 0.034) and shorter survival (median not reached in females vs 9 months in males, P = 0.008) after the autograft. Median Kaplan-Meier DFS of the autografted patients was 29 months in the 17 patients younger than 40 vs 9 months in the older cases, but the difference was not significant (P = 0.15). Gender was not a prognostic factor of DFS and survival in patients consolidated with chemotherapy alone.
Of the six autografted patients with RAEB-T at the onset of chemotherapy, four relapsed, 7-14 months after transplantation; the remaining two were still in CR 11 and 36 months after transplantation. Of the seven autografted patients with RAEB at the onset of chemotherapy, two relapsed, 4 and 11 months after transplantation; the remaining five were still in CR, 8-22 months after transplantation. Of the 11 autografted patients who had AML at the onset of chemotherapy, seven relapsed, 5-23 months after transplantation; the remaining two were still in CR 10-52 months after transplantation.
Discussion
Relapse after CR achievement with intensive chemotherapy in MDS occurs in a large majority of patients. In our experience based on 71 MDS patients who achieved CR with intensive chemotherapy and had greater than 4 years follow-up, only 6% remained in first CR. 14 In patients who cannot be allografted, treatment intensification after CR achievement is therefore warranted. Clonality studies in MDS suggest that, in the majority of cases, lymphocytes do not belong to the malignant clone. 25 This suggests the persistence, in those patients, of polyclonal bone marrow progenitors that could be used to reconstitute normal hematopoiesis after myeloablative treatment. In addition, although those studies were performed in small numbers of patients, Carella et al 20 found, in nine MDS patients with abnormal karyotype, that stem cells collected after intensive chemotherapy had normal karyotype in six cases, whereas Delforge et al, 26 in four of five MDS patients tested, found those collected stem cells to be non-clonal using X chromosome linked polymorphisms. These findings provide a basis for using autologous stem cell transplantation in MDS. Reports on results of ABMT and APSCT in MDS have all been retrospective, and included the large European Bone Marrow Transplantation (EBMT) group experience with ABMT 21 and small series of ABMT or APSCT. [18] [19] [20] Those studies showed that ABMT and APSCT were feasible in MDS having achieved CR with intensive chemotherapy. In particular, engraftment was obtained in all transplanted cases, after delays similar to those seen in AML.
The present study is the first to prospectively assess ABMT and APSCT in MDS. In this study, results of induction treatment prior to ABMT and APSCT had been similar to those previously reported in the literature in MDS treated with intensive chemotherapy, [8] [9] [10] [11] [12] [13] [14] 15, 17 ie a relatively low CR rate. Stem cell transplantation could be performed in 62% of patients aged р55 years who achieved CR after intensive chemotherapy, a relatively high figure if compared to the percentage of patients with de novo AML having achieved CR who undergo ABMT in multicenter trials where ABMT is planned for consolidation. 27 The main reasons for not performing transplantation were early relapse, poor clinical condition and insufficient bone marrow harvest. The five early relapses occurred very soon after CR achievement (1-2 months), making difficult any attempt to collect bone marrow or peripheral blood stem cells. Unfavorable karyotype (ie −7, +8 or complex abnormalities) was observed in three of the three patients with early relapse in whom karyotype was performed. Most of the other patients with unfavorable karyotype could not be autografted because they did not reach CR with induction chemotherapy. Indeed, only two of the 24 autografted cases (8%) had unfavorable karyotype as compared to 22 of the 63 (65%) patients aged р55 years included in the trial and in whom karyotype was performed. This confirmed the strong prognostic implication of karyotype in MDS treated with intensive chemotherapy.
ABMT was impossible due to poor bone marrow harvest in four cases. In two additional cases, bone marrow harvest was poor but subsequent adequate PSC collection was possible, allowing APSCT. Eight of the 10 PSC collections made in our study had adequate CD34 levels. In the study of Demuynck et al, 19 bone marrow harvest was insufficient in three of six patients, and one of them subsequently had an adequate PSC harvest. However, four of the 11 PSC harvests were insufficient. In the work of Carella et al, 20 PSC harvest after mobilization by chemotherapy and G-CSF was quantitatively sufficient in only six of nine patients. PSC harvest therefore remains a problem in some MDS patients.
As for ABMT, all the patients in our study who underwent APSCT had stem cell engraftment. Duration of neutropenia tended to be shorter although not significantly so after APSCT, as compared to ABMT. In the results of the Leuven's group, 19 differences between engraftment after APSCT and ABMT were more pronounced. Toxicity of ABMT and APSCT were acceptable with three treatment-related deaths in the 16 ABMT and none in the eight APSCT. Treatment-related mortality rates reported in previous studies were one in seven, 18 one in five 19 and seven in 79. 21 Median DFS of the 24 autografted patients was 29 months from transplantation in the present study. However, follow-up was still too short in many patients to determine if ABMT and ABSCT would give prolonged CR duration in some patients, by comparison with consolidation chemotherapy. Of note, was that patients with RAEB-T and normal karyotype, ie the only population of MDS that obtained relatively favorable long-term results with intensive chemotherapy in our experience, 13 represented only 20% of the autografted patients. In the study of Laporte et al, of the seven MDS patients autografted in CR with marrow purged by mafosfamide, four patients relapsed at 2.5, 6, 8 and 25 months from transplantation, and two remained in persistent CR at 10 and 28 months from ABMT, respectively. Of the five autografted patients reported by Demuynck et al, 19 four patients were in persistent CR but with short follow-up (4-14 months from transplantation). In the large report of the EBMT group, 21 DFS and relapse rates were 34% and 64% at 2 years, respectively.
Age emerged as a prognostic factor of outcome after ABMT in the EBMT experience. The 2 year DFS of patients aged less than 40 years was significantly better than that of older patients: 39% vs 25%, respectively. In the present study, median DFS was 29 months in the 17 patients younger than 40 vs 9 in the older cases, but this difference was not significant. On the other hand, gender was a prognostic factor in autografted MDS patients in our study, with females having significantly fewer relapses. Gender was, however, not associated with response to induction chemotherapy and did not influence outcome in patients consolidated with chemotherapy alone. MDS has an overall poorer prognosis in males, but we had previously shown that the survival advantage of females in MDS was mostly due to differences in non-MDS deaths rather than to a more aggressive course of MDS in males. 23 Thus, the better outcome of females after autograft remains unexplained, although it will have to be confirmed in larger numbers of patients.
In conclusion, this prospective study showed that autologous stem cell transplantation is possible in a selected group of MDS patients which includes about two-thirds of MDS eligible for intensive chemotherapy and who achieve CR with this treatment. Our results suggest that PBSC collection may be more adequate than marrow collection and could increase the percentage of MDS patients who can be autografted in CR. Although results of the present study are encouraging, further studies are needed to determine if ABMT and APSCT will increase CR duration in some patients, by comparison with consolidation chemotherapy.
